Clinical trial
Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated…
NCT00008242 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00008242 |
|---|---|
| Title | Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma |
| Official title | A Phase II Clinical Trial Of Thalidomide, Adramycin And Dexamethasone (TAD) As Initial Therapy For The Treatment Of Multiple Myeloma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | dexamethasone, doxorubicin hydrochloride, thalidomide |
| Start date | Aug 1, 2000 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | May 4, 2004 |
| Last update posted | Mar 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: